BiotechTube

YH42946

Phase 1/2Recruiting
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

NSCLC (Non-small Cell Lung Cancer)

Conditions

NSCLC (Non-small Cell Lung Cancer), Solid Tumor

Trial Timeline

Oct 2, 2024 → Jul 29, 2028

NCT ID
NCT06616766

About YH42946

YH42946 is a phase 1/2 stage product being developed by Yuhan for NSCLC (Non-small Cell Lung Cancer). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06616766. Target conditions include NSCLC (Non-small Cell Lung Cancer), Solid Tumor.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT06616766Phase 1/2Recruiting

Competing Products

20 competing products in NSCLC (Non-small Cell Lung Cancer)

See all competitors
ProductCompanyStageHype Score
Bevacizumab in Combination With Paclitaxel/Carboplatin + IBI305 in Combination with Paclitaxel/CarboplatinWuXi BiologicsPhase 3
74
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
BBP-398 + osimertinibLianBioPhase 1
25
BA3071 + Nivolumab + Pembrolizumab + Pemetrexed (Alimta)BioAtlaPhase 1/2
33
HER3-DXd + HER3-DXd + Osimertinib + Osimertinib + HER3-DXd + HER3-DXd + OsimertinibDaiichi SankyoPhase 1
33
U3-1287 + Erlotinib + PlaceboDaiichi SankyoPhase 1/2
41
DS-1205c + OsimertinibDaiichi SankyoPhase 1
33
Datopotamab deruxtecan (Dato-DXd) + DocetaxelDaiichi SankyoPhase 3
77
Datopotamab deruxtecan + Durvalumab + Carboplatin + AZD2936 + MEDI5752 + AZD7789Daiichi SankyoPhase 1
33
Datopotamab deruxtecan + KEYTRUDA® + Carboplatin + CisplatinDaiichi SankyoPhase 1
33
HER3-DXd (FL-DP) + HER3-DXd (CTM-1 Lyo-DP) + HER3-DXd (CTM-3 Lyo-DP)Daiichi SankyoPhase 1
33
CS-7017 + erlotinibDaiichi SankyoPhase 2
52
gilteritinibAstellas PharmaPhase 1
33
OSI-906 + erlotinib + placeboAstellas PharmaPhase 2
52
naquotinib + midazolamAstellas PharmaPhase 1
33
OSI-906 + Erlotinib + PlaceboAstellas PharmaPhase 2
52
ExisulindAstellas PharmaPhase 1/2
41
naquotinibAstellas PharmaPhase 1
33
ASP8273Astellas PharmaPhase 2
52
TarcevaAstellas PharmaPhase 1
33

Other Products from Yuhan

generic formulation of atorvastatin (Atorva®) + branded formulation of atorvastatin (Lipitor®)Approved
85
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgApproved
85
Anplag Tab. 100mg bid + Anplag Tab. 100mg tidApproved
85
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgApproved
85
Atorvastatin 20mg loading + Atorvastatin 80mg loadingApproved
85